Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
ANASTROZOLE
DOMINION PHARMACAL
L02BG03
ANASTROZOLE
1MG
TABLET
ANASTROZOLE 1MG
ORAL
30
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0128681001; AHFS:
APPROVED
2016-12-01
PRODUCT MONOGRAPH Pr DOM-ANASTROZOLE Anastrozole Tablets 1 mg Non-Steroidal Aromatase Inhibitor DOMINION PHARMACAL Date of Preparation : 6111 Royalmount Ave., Suite 100 December 1, 2016 Montréal, Québec, H4P 2T4 Submission Control No.: 185300 _ _ _Dom-ANASTROZOLE Product Monograph _ _Page 2 of 53_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................23 SPECIAL HANDLING INSTRUCTIONS .......................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................23 PART II: SCIENTIFIC INFORMATION ...............................................................................24 PHARMACEUTICAL INFORMATION ..........................................................................24 CLINICAL TRIALS .................................................................................. Կարդացեք ամբողջական փաստաթուղթը